⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518606 | 1.00 | — | — | |
| SCHEMBL5365 | 1.00 | — | — | |
| SCHEMBL22287426 | 1.00 | — | — | |
| Ethane SCHEMBL21628349 | 0.94 | — | — | |
| Methylene Chloride SCHEMBL28988958 | 0.91 | — | — | |
| Methylene Chloride SCHEMBL28988955 | 0.91 | — | — | |
| SCHEMBL5364993 | 0.85 | LMNA (0.44) | — | |
| SCHEMBL282885 | 0.85 | — | — | |
| SCHEMBL282891 | 0.85 | — | — | |
| SCHEMBL4208 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| US-12540126-B2 | Method for preparing oxetan-2-ylmethanamine | ACCELA CHEMBIO CO., LTD. (CN) | 2026-02-03 | — | — | US | disclosed |
| EP-4323354-B1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20200255406-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2020-08-13 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3555064-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2018109607-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |